Comparison of Phenytoin, Valproate and Levetiracetam in Pediatric Convulsive Status Epilepticus: A Randomized Double-blind Controlled Clinical Trial.
Journal
Indian pediatrics
ISSN: 0974-7559
Titre abrégé: Indian Pediatr
Pays: India
ID NLM: 2985062R
Informations de publication
Date de publication:
15 03 2020
15 03 2020
Historique:
entrez:
22
3
2020
pubmed:
22
3
2020
medline:
31
3
2021
Statut:
ppublish
Résumé
To compare the efficacy of phenytoin, valproate, and levetiracetam in the management of pediatric convulsive status epilepticus. Randomized double-blind controlled clinical trial. Pediatric critical care division in a tertiary care institute from June, 2016 to December, 2018. 110 children aged three month to 12 year with convulsive status epilepticus. Patients not responding to 0.1 mg/kg intravenous lorazepam were randomly assigned (1:1:1) to receive 20 mg/kg of phenytoin (n=35) or valproate (n=35) or levetiracetam (n=32) over 20 minutes. Patients with nonconvulsive status epilepticus, recent hemorrhage, platelet count less than 50,000 or International normalized ratio (INR) more than 2, head injury or neurosurgery in the past one-month, liver or kidney disease, suspected or known neurometabolic or mitochondrial disorders or structural malformations, and allergy to study drugs; and those who were already on any one of the study drugs for more than one month or had received one of the study drugs for current episode, were excluded. The primary outcome was the proportion of patients that achieved control of convulsive status epilepticus at the end of 15 minutes after completion of the study drug infusion. Secondary outcomes were time to control of seizure, rate of adverse events, and the requirement of additional drugs to control seizure, length of ventilation, hospital stay, and functional status after three months (Glasgow Outcome Scale). The study was stopped after the planned mid-interim analysis for futility. Intention to treat analysis was done. There was no difference in primary outcome in phenytoin (31/35, 89%), valproate (29/35, 83%), and levetiracetam (30/32, 94%) (P=0.38) groups. There were no differences between the groups for secondary outcomes. One patient in the phenytoin group had a fluid-responsive shock, and one patient in the valproate group died due to encephalopathy and refractory shock. Phenytoin, valproate, and levetiracetam were equally effective in controlling pediatric convulsive status epilepticus.
Substances chimiques
Anticonvulsants
0
Levetiracetam
44YRR34555
Valproic Acid
614OI1Z5WI
Phenytoin
6158TKW0C5
Types de publication
Comparative Study
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
222-227Commentaires et corrections
Type : CommentIn